Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion type Assertion NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_head.
- NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion description "[The purpose of the study was to explore optimal combinations of currently actively developed drugs for dually targeting the Ras ? Raf ? MAPK kinase (MEK) ? MAPK/ERK (MAPK) and the phosphatidylinositol 3-kinase/Akt pathways as effective treatments for thyroid cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_provenance.
- NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion evidence source_evidence_literature NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_provenance.
- NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion SIO_000772 22090271 NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_provenance.
- NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion wasDerivedFrom befree-20150227 NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_provenance.
- NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_assertion wasGeneratedBy ECO_0000203 NP376835.RAVaClzMkTu7NSn7iwZ2g25ctJovFk0gN_PKppLp63ThE130_provenance.